依托北京大学建设的恶性肿瘤发病机制及转化研究教育部重点实验室于2007年12月立项建设，2008年6月通过建设计划专家论证，2010年5月通过建设验收，2016年12月接受教育部评估考核。现任重点实验室主任季加孚教授，学术委员会主任程京院士。

　　重点实验室的研究领域及方向为：肿瘤病因及发病机制的研究；肿瘤分子流行病学及高危人群的干预研究；肿瘤预警与早期诊断的研究；肿瘤侵袭转移的研究；肿瘤个体化治疗及诊治新方法的研究。

　　实验室有一支专门从事肿瘤基础研究及应用基础研究的科研队伍，既有国际上具学术影响力的多名学科带头人，又具有较强开拓创新能力的年轻学术骨干，有较强的整体研究实力和国际学术竞争能力。目前有中科院院士1人，中国工程院院士1人（2016年引进），美国医学科学院院士1人，长江学者特聘教授3人，国家杰出青年基金获得者5人，青年千人1人。建有胃癌和食管癌两大高发现场和符合国际标准的生物样本库。

　　重点实验室以我国常见恶性肿瘤为主攻方向，充分利用已建立的肿瘤高发现场及丰富的临床病例资源，发挥流行病学、遗传学、病因学、分子生物学、病理学及临床医学多学科协作优势，开展了肿瘤病因与发病机制、高危人群干预及早诊早治、临床诊疗靶点发现及药物研发研究，在胃癌、食管癌、肝癌、肺癌、乳腺癌、恶性黑色素瘤等肿瘤发病机制及转化研究方面取得了重要进展。例如，首次采用随机对照研究证明根除幽门螺杆菌感染可以有效降低人群胃癌发病率，研究成果成为世界卫生组织（WHO）制定胃癌预防策略的依据；耐药性恶性黑色素瘤的新型个体化治疗方案在国际上引起广泛关注，并纳入国际指南；胃癌综合防治体系建立取得重要成果，得到国际同行的高度认可，季加孚教授当选为国际胃癌学会主席，获得2017年第十二届世界胃癌大会主办权并成功举办，使中国首次成为世界胃癌大会的主办国。同时，发现了新型组蛋白修饰酶HAT4和JMJD2B等；制备了能够靶向钙离子通道蛋白a2d1的单克隆抗体1B50-1，有清除肿瘤起始细胞的作用；研发了抑制肿瘤血管生成的肽类新药FpAT，获得了国家食品药品监督管理总局CFDA颁发的1.1类抗肿瘤新药的临床试验批件。研究结果发表在Lancet Oncol、Cancer Cell、J Clin Oncol、Gut、JNCI、Nat Commun、Genome Biol等国际知名刊物上。

　　

　　机构负责人：季加孚

　　联系人：贾淑芹

　　邮箱：kjc126@163.con

　　电话：88196926

　　地址：北京市海淀区阜成路52号

　　网址：https://www.bjcancer.org/Html/News/Main/119.html

　　

　　Ministry of Education

　　Key Laboratory of Carcinogenesis and Translational Research

 

　　The Ministry of Education (MOE) Key Laboratory of Carcinogenesis and Translational Research is affiliated to Peking University. It was officially approved in December 2007, verified by the expert panel in June 2008, and completed, checked and accepted in May 2010. In December 2016, it was examined and evaluated by the MOE. The director of the Key Laboratory is Prof. Ji Jia-fu, and the chairman of the Academic Committee is Prof. Cheng Jing, a member of the Chinese Academy of Engineering.

　　The Key Laboratory research areas include cancer etiology and pathogenesis, molecular epidemiology and intervention in the high-risk population, cancer early detection, metastasis, individualized therapy and new methods of diagnosis and treatment, etc.

　　The Key Laboratory has a research team engaged in cancer related basic and translational research, which consists of world-renowned academic pacemakers and promising and innovative young scientists, making it strong in research capacity and international academic competitiveness. Currently, the research team has one member of the Chinese Academy of Sciences, one member of the Chinese Academy of Engineering (recruited in 2016), one member of the American Academy of Medical Sciences, three chair professors of “Chang Jiang Scholars Program”, five awardees of the National Science Fund for Distinguished Young Scholars, and one member of the Young Overseas High-Level Talents Introduction Plan. Two population-based research fieldsin the high risk areas of gastric cancer and esophageal cancer have been set up and a bio-bank in line with international standards has been established.

　　Focusing on common cancers in China, the Key Laboratory takes full advantage of the two established population-based cohorts, the large number of clinical cancer cases, and its strength in multidisciplinary cooperation among epidemiology, genetics, etiology, molecular biology, pathology and clinical medicine to carry out research in cancer etiology and pathogenesis; intervention, cancer early diagnosis and treatment for high-risk population; identification of targets for cancer diagnosis and treatment and corresponding drug research and development, and has made significant progress in carcinogenesis and translational research in gastric cancer, esophageal cancer, liver cancer, lung cancer, breast cancer, malignant melanoma, etc. For example, we have, for the first time, demonstrated that eradication of Helicobacter pylori can reduce the incidence of gastric cancer through randomized controlled intervention trial, and the findings have been adopted by the World Health Organization (WHO) as evidence for development of strategies for gastric cancer prevention. We developed the new individualized treatment protocol for drug-resistant malignant melanoma, which attracted great international attention and was integrated into the international guidelines. The comprehensive gastric cancer prevention and control system we established was highly recognized by the international community, and Professor Ji Jia-fu was elected as chairman of the International Gastric Cancer Association, and China, for the first time, won the bid for hosting the 12^th International Gastric Cancer Conference in 2017. The major findings also included the discovery of new histone-modifying enzymes of HAT4 and JMJD2B; production ofmonoclonal antibody 1B50-1 which can target calcium channel protein a2d1 and eliminate tumor initiating cells; development of a new peptide drug FpAT that inhibits tumor angiogenesis, which has obtained clinical trial approval of Class 1.1 new antitumor drug issued by the China Food and Drug Administration. The findings were published in the internationally renowned publications such as Lancet Oncol, Cancer Cell, J Clin Oncol, Gut, JNCI, Nat Commun, and Genome Biol.

　　

　　Director: Ji Jia-fu

　　Contact: Jia Shu-qin

　　E-mail: kjc126@163.con

　　Phone: 8610-88196926

　　Address: 52 Fucheng Road, Haidian District, Beijing

　　Website: https://www.bjcancer.org/Html/News/Main/119.html